Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Improves R&D Benchmark: 80% Of Pre-Clinical Candidates Enter Trials

Executive Summary

Bristol-Myers Squibb has improved its early development success rate to the level that 80% of recommended development candidates make it into human testing, the company said during its R&D update Nov. 17

You may also be interested in...



Bristol Late-Stage Pipeline Reflects Success Of In-House Development

Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III

Bristol Late-Stage Pipeline Reflects Success Of In-House Development

Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III

Aventis Drug Candidate Assessment Finds Half Fail Due To Safety Concerns

Almost half of Aventis' new drug candidates fail during development because of safety or toxicity concerns, the drug manufacturer's internal data from 2003 show

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel